Department of Radiation Oncology, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin, Gyeonggi-Do, Korea.
Department of Radiation Oncology, Yonsei Cancer Center, Heavy Ion Therapy Research Institute, Yonsei University College of Medicine, Seoul, Korea.
Radiat Oncol. 2022 Dec 1;17(1):197. doi: 10.1186/s13014-022-02165-5.
Although postoperative radiotherapy (PORT) is demonstrably effective in local control of head and neck adenoid cystic carcinoma (HNACC), its application is controversial and the subset of patients who would benefit most from PORT is unknown. Herein, we analyzed the data of HNACC patients to clarify the role of PORT.
We retrospectively reviewed 187 patients with nonmetastatic HNACC who underwent surgical resection between 2005 and 2019. The study endpoints were locoregional failure-free survival (LRFFS), progression-free survival (PFS), and overall survival (OS). Subgroup analysis and recursive partitioning analysis (RPA) were performed to identify patients most likely to benefit from PORT.
With a median follow-up of 84.7 months, the 5-year LRFFS, PFS, and OS were 70.0%, 52.6%, and 86.4%, respectively. Survival was significantly shorter in patients who experienced local failure than in those who did not (5-year OS: 88.1% vs. 80.5%, P = 0.001). The local failure rate was significantly lower in patients who underwent PORT (16.9% vs. 31.0%, P = 0.021), despite the high frequency of adverse factors. Especially, significant decreases in local failure and similar OS rates could be obtained after PORT among patients with positive margins, T2-4 stage disease, and minor salivary gland tumors. The RPA model for PFS categorized patients into four groups according to three prognostic factors (T-stage, location, and sex). The RPA model for LRFFS and OS suggested three groups based on two factors (T-stage, margin for LRFFS; T-stage, grade 3 for OS).
PORT could prevent dismal survival, while significantly reducing local failures in high-risk HNACC patients.
尽管术后放疗(PORT)在局部控制头颈部腺样囊性癌(HNACC)方面具有明显的疗效,但它的应用仍存在争议,并且哪些患者最能从 PORT 中获益也尚不清楚。在此,我们分析了 HNACC 患者的数据,以阐明 PORT 的作用。
我们回顾性分析了 2005 年至 2019 年间接受手术切除的 187 例非转移性 HNACC 患者。研究终点为局部无复发生存(LRFFS)、无进展生存(PFS)和总生存(OS)。进行了亚组分析和递归分区分析(RPA),以确定最有可能从 PORT 中获益的患者。
中位随访 84.7 个月后,5 年 LRFFS、PFS 和 OS 分别为 70.0%、52.6%和 86.4%。与未发生局部失败的患者相比,发生局部失败的患者生存时间明显缩短(5 年 OS:88.1% vs. 80.5%,P=0.001)。尽管存在大量不良因素,但接受 PORT 的患者局部失败率明显较低(16.9% vs. 31.0%,P=0.021)。特别是在边缘阳性、T2-4 期疾病和小唾液腺肿瘤患者中,PORT 后可显著降低局部失败率,同时保持相似的 OS 率。PFS 的 RPA 模型根据三个预后因素(T 分期、位置和性别)将患者分为四组。LRFFS 和 OS 的 RPA 模型基于两个因素(LRFFS 的 T 分期、边缘状态;OS 的 T 分期、3 级)将患者分为三组。
PORT 可预防不良预后,同时显著降低高危 HNACC 患者的局部失败率。